{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:05:28Z","timestamp":1792242328947,"version":"4.4.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Lemborexant (LEM) is a dual orexin receptor antagonist (DORA) approved in multiple countries including the USA, Japan, Canada, Australia, and several Asian countries for the treatment of insomnia in adults. As a compound with central nervous system activity, it is important to understand the abuse potential of LEM with respect to public health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This review discusses data for LEM relevant to each of the 8 factors of the United States Controlled Substances Act.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>LEM did not demonstrate abuse potential in nonclinical testing and was associated with a low incidence of abuse-related adverse events in clinical study participants with insomnia disorder. Similar to other DORAs that have been evaluated (eg., almorexant, suvorexant (SUV), and daridorexant), LEM and the positive controls (zolpidem and SUV) also showed drug liking in a phase 1 abuse potential study that enrolled subjects who used sedatives recreationally. However, internet surveillance of SUV and the FDA Adverse Events Reporting System suggests that drugs in the DORA class display very low abuse-related risks in the community. Additionally, as described in FDA-approved labeling, it does not carry physical dependence and withdrawal risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LEM, similar to most other prescription insomnia medications, was placed into Schedule IV. However, LEM and other drugs in the DORA class may have a lower potential for abuse as suggested by real-world postmarketing data from federal surveys and internet surveillance, and thus may have lower risks to public health than Schedule IV benzodiazepines and nonbenzodiazepine hypnotics that potentiate GABA signaling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-023-06320-y","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T03:06:16Z","timestamp":1675739176000},"page":"699-711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act"],"prefix":"10.1007","volume":"240","author":[{"given":"Margaret","family":"Moline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Beuckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishani","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Setnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack E.","family":"Henningfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"6320_CR1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2165\/00002512-200522090-00004","volume":"22","author":"H Allain","year":"2005","unstructured":"Allain H, Bentu\u00e9-Ferrer D, Polard E, Akwa Y, Patat A (2005) Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 22:749\u2013765","journal-title":"Drugs Aging"},{"key":"6320_CR2","doi-asserted-by":"publisher","first-page":"105053","DOI":"10.1016\/j.yrtph.2021.105053","volume":"127","author":"S Asakura","year":"2021","unstructured":"Asakura S, Shiotani M, Gauvin DV, Fujiwara A, Ueno T, Bower N, Beuckmann CT, Moline M (2021) Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant. Regul Toxicol Pharmacol 127:105053","journal-title":"Regul Toxicol Pharmacol"},{"key":"6320_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0376-8716(00)00123-X","volume":"61","author":"NA Ator","year":"2000","unstructured":"Ator NA (2000) Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons. Drug Alcohol Depend 61:55\u201368","journal-title":"Drug Alcohol Depend"},{"key":"6320_CR4","doi-asserted-by":"crossref","unstructured":"Baimel C, Bartlett SE, Chiou LC, Lawrence AJ, Muschamp JW, Patkar O, Tung LW, Borgland SL (2015) Orexin\/hypocretin role in reward: implications for opioid and other addictions. Br J Pharmacol 172:334\u2013348","DOI":"10.1111\/bph.12639"},{"key":"6320_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1124\/jpet.117.241422","volume":"362","author":"CT Beuckmann","year":"2017","unstructured":"Beuckmann CT, Suzuki M, Ueno T, Nagaoka K, Arai T, Higashiyama H (2017) In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist. J Pharmacol Exp Ther 362:287\u2013295","journal-title":"J Pharmacol Exp Ther"},{"key":"6320_CR6","doi-asserted-by":"publisher","first-page":"zsz076","DOI":"10.1093\/sleep\/zsz076","volume":"42","author":"CT Beuckmann","year":"2019","unstructured":"Beuckmann CT, Ueno T, Nakagawa M, Suzuki M, Akasofu S (2019) Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep\/wake regulation. Sleep 42:zsz076","journal-title":"Sleep"},{"key":"6320_CR7","unstructured":"BLUELIGHT (2016) Post #5 from I B Profane"},{"key":"6320_CR8","doi-asserted-by":"publisher","first-page":"e13248","DOI":"10.1111\/jsr.13248","volume":"30","author":"ML Boof","year":"2021","unstructured":"Boof ML, Dingemanse J, Brunke M, Esselmann A, Heymer P, Kestermann O, Lederer K, Fietze I, Ufer M (2021a) Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease. J Sleep Res 30:e13248","journal-title":"J Sleep Res"},{"issue":"6","key":"6320_CR9","doi-asserted-by":"publisher","first-page":"zsaa275","DOI":"10.1093\/sleep\/zsaa275","volume":"44","author":"ML Boof","year":"2021","unstructured":"Boof ML, Dingemanse J, Lederer K, Fietze I, Ufer M (2021b) Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep 44(6):zsaa275","journal-title":"Sleep"},{"key":"6320_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.yrtph.2017.03.006","volume":"86","author":"S Born","year":"2017","unstructured":"Born S, Gauvin DV, Mukherjee S, Briscoe R (2017) Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regul Toxicol Pharmacol 86:181\u2013192","journal-title":"Regul Toxicol Pharmacol"},{"key":"6320_CR11","volume-title":"Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics","author":"LLKB Brunton","year":"2022","unstructured":"Brunton LLKB (2022) Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics, 14th edn. McGraw Hill, New York","edition":"14"},{"key":"6320_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/pme.12524","volume":"16","author":"SF Butler","year":"2015","unstructured":"Butler SF, McNaughton EC, Black RA (2015) Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. Pain Med 16:119\u2013130","journal-title":"Pain Med"},{"key":"6320_CR13","unstructured":"Calderon S, Hawkins EG, Reissig C, Chiapperino D (2020) Evalulation of human abuse potential (HAP) studies for drugs with novel mechanisms of action The College on Problems of Drug Dependence 2020 Scientific Meeting Virtual Experience"},{"key":"6320_CR14","doi-asserted-by":"publisher","first-page":"145902","DOI":"10.1016\/j.brainres.2018.08.005","volume":"1731","author":"EJ Campbell","year":"2020","unstructured":"Campbell EJ, Marchant NJ, Lawrence AJ (2020) A sleeping giant: suvorexant for the treatment of alcohol use disorder? Brain Res 1731:145902","journal-title":"Brain Res"},{"key":"6320_CR15","unstructured":"Caro Y, Calderon S, Chen L, Wittayanukorn S, Karami S, Muhammad S, Adereti M, Gill R, Radin R, Hawkins1 E, Reissig C, Chiapperino D (2022) Human Abuse Potential Study Results in the Context of Abuse Detected Postmarketing Annual Meeting of the College on Problems of Drug Dependence. The College on Problems of Drug Dependence, Minneapolis"},{"key":"6320_CR16","doi-asserted-by":"publisher","first-page":"e13021","DOI":"10.1111\/jsr.13021","volume":"29","author":"JY Cheng","year":"2020","unstructured":"Cheng JY, Filippov G, Moline M, Zammit GK, Bsharat M, Hall N (2020) Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: a randomized, double-blind, placebo-controlled, crossover study. J Sleep Res 29:e13021","journal-title":"J Sleep Res"},{"key":"6320_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40261-021-01018-5","volume":"41","author":"JY Cheng","year":"2021","unstructured":"Cheng JY, Moline M, Zammit GK, Filippov G, Bsharat M, Hall N (2021a) respiratory safety of lemborexant in healthy subjects: a single-dose, randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 41:449\u2013457","journal-title":"Clin Drug Investig"},{"key":"6320_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40261-021-01018-5","volume":"41","author":"JY Cheng","year":"2021","unstructured":"Cheng JY, Moline M, Zammit GK, Filippov G, Bsharat M, Hall N (2021b) Respiratory safety of lemborexant in healthy subjects: a single-dose, randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 41:449\u2013457","journal-title":"Clin Drug Investig"},{"issue":"S 1","key":"6320_CR19","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.drugalcdep.2005.11.027","volume":"83","author":"EJ Cone","year":"2006","unstructured":"Cone EJ (2006) Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend 83(S 1):S31\u2013S39","journal-title":"Drug Alcohol Depend"},{"key":"6320_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40263-014-0150-x","volume":"28","author":"HG Cruz","year":"2014","unstructured":"Cruz HG, Hoever P, Chakraborty B, Schoedel K, Sellers EM, Dingemanse J (2014) Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users. CNS drugs 28:361\u2013372","journal-title":"CNS drugs"},{"key":"6320_CR21","doi-asserted-by":"publisher","first-page":"e12946","DOI":"10.1111\/adb.12946","volume":"26","author":"JE Fragale","year":"2021","unstructured":"Fragale JE, James MH, Aston-Jones G (2021a) Intermittent self-administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system. Addict Biol 26:e12946","journal-title":"Addict Biol"},{"key":"6320_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000514965","volume":"45","author":"JE Fragale","year":"2021","unstructured":"Fragale JE, James MH, Avila JA, Spaeth AM, Aurora RN, Langleben D, Aston-Jones G (2021b) The insomnia-addiction positive feedback loop: role of the orexin system. Front Neurol Neurosci 45:117\u2013127","journal-title":"Front Neurol Neurosci"},{"key":"6320_CR23","unstructured":"Griffiths RR, Ator NA (1980) Benzodiazepine self-administration in animals and humans: a comprehensive literature review. NIDA Res Monogr 22\u201336"},{"key":"6320_CR24","unstructured":"Griffiths RR, Bigelow GE, Henningfield JE (1980) Similarities in animal and human drug-taking behavior. In: Mello NK (ed) Advances in substance abuse. JAI Press, Inc., Greenwich, CT, pp 1\u201390"},{"issue":"Suppl 9","key":"6320_CR25","first-page":"31","volume":"66","author":"RR Griffiths","year":"2005","unstructured":"Griffiths RR, Johnson MW (2005) Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 66(Suppl 9):31\u201341","journal-title":"J Clin Psychiatry"},{"key":"6320_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/BF02244196","volume":"103","author":"RR Griffiths","year":"1991","unstructured":"Griffiths RR, Lamb RJ, Sannerud CA, Ator NA, Brady JV (1991) Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology 103:154\u2013161","journal-title":"Psychopharmacology"},{"key":"6320_CR27","first-page":"1199","volume":"260","author":"RR Griffiths","year":"1992","unstructured":"Griffiths RR, Sannerud CA, Ator NA, Brady JV (1992) Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J Pharmacol Exp Ther 260:1199\u20131208","journal-title":"J Pharmacol Exp Ther"},{"key":"6320_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s13181-013-0294-y","volume":"9","author":"N Gunja","year":"2013","unstructured":"Gunja N (2013) In the Zzz zone: the effects of Z-drugs on human performance and driving. J Med Toxicol 9:163\u2013171","journal-title":"J Med Toxicol"},{"key":"6320_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00213-008-1079-x","volume":"199","author":"M Haney","year":"2008","unstructured":"Haney M, Spealman R (2008) Controversies in translational research: drug self-administration. Psychopharmacology 199:403\u2013419","journal-title":"Psychopharmacology"},{"key":"6320_CR30","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.2105\/AJPH.2015.302723","volume":"105","author":"RN Hansen","year":"2015","unstructured":"Hansen RN, Boudreau DM, Ebel BE, Grossman DC, Sullivan SD (2015) Sedative hypnotic medication use and the risk of motor vehicle crash. Am J Public Health 105:e64\u2013e69","journal-title":"Am J Public Health"},{"key":"6320_CR31","doi-asserted-by":"publisher","first-page":"109220","DOI":"10.1016\/j.neuropharm.2022.109220","volume":"218","author":"JE Henningfield","year":"2022","unstructured":"Henningfield JE, Coe MA, Griffiths RR, Belouin SJ, Berger A, Coker AR, Comer SD, Heal DJ, Hendricks PS, Nichols CD, Sapienza F, Vocci FJ, Zia FZ (2022) Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. Neuropharmacology 218:109220","journal-title":"Neuropharmacology"},{"key":"6320_CR32","doi-asserted-by":"publisher","first-page":"eabn8238","DOI":"10.1126\/scitranslmed.abn8238","volume":"14","author":"AS Huhn","year":"2022","unstructured":"Huhn AS, Finan PH, Gamaldo CE, Hammond AS, Umbricht A, Bergeria CL, Strain EC, Dunn KE (2022) Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Sci Transl Med 14:eabn8238","journal-title":"Sci Transl Med"},{"key":"6320_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fendo.2013.00018","volume":"4","author":"A Inutsuka","year":"2013","unstructured":"Inutsuka A, Yamanaka A (2013a) The physiological role of orexin\/hypocretin neurons in the regulation of sleep\/wakefulness and neuroendocrine functions. Front Endocrinol 4:18","journal-title":"Front Endocrinol"},{"key":"6320_CR34","first-page":"29","volume":"75","author":"A Inutsuka","year":"2013","unstructured":"Inutsuka A, Yamanaka A (2013b) The regulation of sleep and wakefulness by the hypothalamic neuropeptide orexin\/hypocretin. Nagoya J Med Sci 75:29\u201336","journal-title":"Nagoya J Med Sci"},{"key":"6320_CR35","doi-asserted-by":"publisher","first-page":"146665","DOI":"10.1016\/j.brainres.2020.146665","volume":"1731","author":"MH James","year":"2020","unstructured":"James MH, Aston-Jones G (2020) Introduction to the special issue: \u201cmaking orexin-based therapies for addiction a reality: what are the steps from here?\u201d. Brain Res 1731:146665","journal-title":"Brain Res"},{"key":"6320_CR36","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41386-020-0619-x","volume":"45","author":"MH James","year":"2020","unstructured":"James MH, Fragale JE, Aurora RN, Cooperman NA, Langleben DD, Aston-Jones G (2020) Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer? Neuropsychopharmacology 45:717\u2013719","journal-title":"Neuropsychopharmacology"},{"key":"6320_CR37","doi-asserted-by":"publisher","first-page":"108359","DOI":"10.1016\/j.neuropharm.2020.108359","volume":"183","author":"MH James","year":"2021","unstructured":"James MH, Fragale JE, O'Connor SL, Zimmer BA, Aston-Jones G (2021) The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse. Neuropharmacology 183:108359","journal-title":"Neuropharmacology"},{"key":"6320_CR38","doi-asserted-by":"crossref","unstructured":"James MH, Stopper CM, Zimmer BA, Koll NE, Bowrey HE, Aston-Jones G (2019) Increased number and activity of a lateral subpopulation of hypothalamic orexin\/hypocretin neurons underlies the expression of an addicted state in rats. Biol Psychiatry 85:925\u2013935","DOI":"10.1016\/j.biopsych.2018.07.022"},{"key":"6320_CR39","doi-asserted-by":"publisher","first-page":"zsaa123","DOI":"10.1093\/sleep\/zsaa123","volume":"43","author":"M K\u00e4rpp\u00e4","year":"2020","unstructured":"K\u00e4rpp\u00e4 M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, Perdomo C, Inoue Y, Ishikawa K, Kubota N (2020a) Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep 43:zsaa123","journal-title":"Sleep"},{"issue":"9","key":"6320_CR40","doi-asserted-by":"publisher","first-page":"zsaa123","DOI":"10.1093\/sleep\/zsaa123","volume":"43","author":"M K\u00e4rpp\u00e4","year":"2020","unstructured":"K\u00e4rpp\u00e4 M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, Perdomo C, Inoue Y, Ishikawa K, Kubota N (2020b) Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep 43(9):zsaa123","journal-title":"Sleep"},{"key":"6320_CR41","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/JCP.0000000000001562","volume":"42","author":"I Landry","year":"2022","unstructured":"Landry I, Hall N, Alur J, Filippov G, Reyderman L, Setnik B, Henningfield J, Moline M (2022a) Acute cognitive effects of the dual orexin receptor antagonist lemborexant compared with suvorexant and zolpidem in recreational sedative users. J Clin Psychopharmacol 42:374\u2013382","journal-title":"J Clin Psychopharmacol"},{"key":"6320_CR42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/JCP.0000000000001561","volume":"42","author":"I Landry","year":"2022","unstructured":"Landry I, Hall N, Aluri J, Filippov G, Reyderman L, Setnik B, Henningfield J, Moline M (2022b) Abuse potential of lemborexant, a dual orexin receptor antagonist, compared with zolpidem and suvorexant in recreational sedative users. J Clin Psychopharmacol 42:365\u2013373","journal-title":"J Clin Psychopharmacol"},{"key":"6320_CR43","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/02698811221080459","volume":"36","author":"I Landry","year":"2022","unstructured":"Landry I, Hall N, Aluri J, Filippov G, Setnik B, Dayal S, Reyderman L, Moline M (2022c) Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: a randomized, placebo-controlled crossover study. J Psychopharmacol 36:745\u2013755","journal-title":"J Psychopharmacol"},{"key":"6320_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/cpdd.817","volume":"10","author":"I Landry","year":"2021","unstructured":"Landry I, Nakai K, Ferry J, Aluri J, Hall N, Lalovic B, Moline ML (2021) Pharmacokinetics, pharmacodynamics, and safety of the dual orexin receptor antagonist lemborexant: findings from single-dose and multiple-ascending-dose phase 1 studies in healthy adults. Clin Pharmacol Drug Dev 10:153\u2013165","journal-title":"Clin Pharmacol Drug Dev"},{"key":"6320_CR45","doi-asserted-by":"publisher","first-page":"fcz025","DOI":"10.1093\/braincomms\/fcz025","volume":"1","author":"A Lerner","year":"2019","unstructured":"Lerner A, Klein M (2019) Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. Brain Commun 1:fcz025","journal-title":"Brain Commun"},{"key":"6320_CR46","doi-asserted-by":"crossref","unstructured":"Mehr JB, Bilotti MM, James MH (2021a) Orexin (hypocretin) and addiction. Trends Neurosci 44:852\u2013855","DOI":"10.1016\/j.tins.2021.09.002"},{"key":"6320_CR47","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1038\/s41386-021-01052-z","volume":"46","author":"JB Mehr","year":"2021","unstructured":"Mehr JB, Mitchison D, Bowrey HE, James MH (2021b) Sleep dysregulation in binge eating disorder and \u201cfood addiction\u201d: the orexin (hypocretin) system as a potential neurobiological link. Neuropsychopharmacology 46:2051\u20132061","journal-title":"Neuropsychopharmacology"},{"key":"6320_CR48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.smrv.2009.10.008","volume":"14","author":"MA Mets","year":"2010","unstructured":"Mets MA, Volkerts ER, Olivier B, Verster JC (2010) Effect of hypnotic drugs on body balance and standing steadiness. Sleep Med Rev 14:259\u2013267","journal-title":"Sleep Med Rev"},{"key":"6320_CR49","unstructured":"Moline M, Cheng JY, Lorch D, Hall N, Shah D (2021a) Respiratory safety of lemborexant in adult and elderly subjects with moderate to severe obstructive sleep apnea; American College of Neuropsychopharmacology (ACNP) Congress, San Juan, Puerto Rico, December 5-8, 2021"},{"key":"6320_CR50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/00325481.2020.1823724","volume":"133","author":"M Moline","year":"2021","unstructured":"Moline M, Zammit G, Yardley J, Pinner K, Kumar D, Perdomo C, Cheng JY (2021b) Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials. Postgrad Med 133:71\u201381","journal-title":"Postgrad Med"},{"key":"6320_CR51","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cpt.2592","volume":"111","author":"C Muehlan","year":"2022","unstructured":"Muehlan C, Brooks S, Vaillant C, Meinel M, Jacobs GE, Zuiker RG, Dingemanse J (2022) Driving performance after bedtime administration of daridorexant, assessed in a sensitive simulator. Clin Pharmacol Ther 111:1334\u20131342","journal-title":"Clin Pharmacol Ther"},{"key":"6320_CR52","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5664\/jcsm.8294","volume":"16","author":"P Murphy","year":"2020","unstructured":"Murphy P, Kumar D, Zammit G, Rosenberg R, Moline M (2020) Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening. J Clin Sleep Med 16:765\u2013773","journal-title":"J Clin Sleep Med"},{"key":"6320_CR53","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.5664\/jcsm.6800","volume":"13","author":"P Murphy","year":"2017","unstructured":"Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, Dhadda S, Hong Q, Giorgi L, Satlin A (2017) Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study. J Clin Sleep Med 13:1289\u20131299","journal-title":"J Clin Sleep Med"},{"key":"6320_CR54","unstructured":"National Survey on Drug Use and Health (2019) Substance Abuse and Mental Health Services Administration, data archive. https:\/\/www.samhsa.gov\/data\/report\/2019-nsduh-detailed-tables. Accessed Dec\u00a02020"},{"key":"6320_CR55","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.neubiorev.2010.10.012","volume":"35","author":"EC O'Connor","year":"2011","unstructured":"O'Connor EC, Chapman K, Butler P, Mead AN (2011) The predictive validity of the rat self-administration model for abuse liability. Neurosci Biobehav Rev 35:912\u2013938","journal-title":"Neurosci Biobehav Rev"},{"key":"6320_CR56","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/clpt.2011.3","volume":"89","author":"L Orriols","year":"2011","unstructured":"Orriols L, Philip P, Moore N, Castot A, Gadegbeku B, Delorme B, Mallaret M, Lagarde E, CESIR Research Group (2011) Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther 89:595\u2013601","journal-title":"Clin Pharmacol Ther"},{"key":"6320_CR57","doi-asserted-by":"publisher","first-page":"145922","DOI":"10.1016\/j.brainres.2018.08.025","volume":"1731","author":"DA Perrey","year":"2020","unstructured":"Perrey DA, Zhang Y (2020) Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res 1731:145922","journal-title":"Brain Res"},{"key":"6320_CR58","first-page":"707","volume":"262","author":"KL Preston","year":"1992","unstructured":"Preston KL, Wolf B, Guarino JJ, Griffiths RR (1992) Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability. J Pharmacol Exp Ther 262:707\u2013720","journal-title":"J Pharmacol Exp Ther"},{"key":"6320_CR59","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1021\/acs.jmedchem.9b01787","volume":"63","author":"M Rappas","year":"2020","unstructured":"Rappas M, Ali AAE, Bennett KA, Brown JD, Bucknell SJ, Congreve M, Cooke RM, Cseke G, de Graaf C, Dor\u00e9 AS, Errey JC, Jazayeri A, Marshall FH, Mason JS, Mould R, Patel JC, Tehan BG, Weir M, Christopher JA (2020) Comparison of Orexin 1 and Orexin 2 ligand binding modes using X-ray crystallography and computational analysis. SJ Med Chem 63:1528\u20131543","journal-title":"SJ Med Chem"},{"key":"6320_CR60","unstructured":"reddit (2015) Main post from FrankensteinzMonster"},{"key":"6320_CR61","unstructured":"reddit (2016) Post #1 from niebula"},{"key":"6320_CR62","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","volume":"238","author":"C Roch","year":"2021","unstructured":"Roch C, Bergamini G, Steiner MA, Clozel M (2021) Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl) 238:2693\u20132708","journal-title":"Psychopharmacology (Berl)"},{"key":"6320_CR63","doi-asserted-by":"crossref","unstructured":"Rosenberg R, Murphy P, Zammit G, Mayleben D,\u00a0Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M (2019)  Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open 2:e1918254","DOI":"10.1001\/jamanetworkopen.2019.18254"},{"key":"6320_CR64","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1037\/1064-1297.3.1.26","volume":"3","author":"CA Sannerud","year":"1995","unstructured":"Sannerud CA, Kaminski BJ, Griffiths RR (1995) Maintenance of H1 antagonists self-injection in baboons. Exp Clin Psychopharmacol 3:26\u201332","journal-title":"Exp Clin Psychopharmacol"},{"key":"6320_CR65","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.neuron.2017.01.014","volume":"93","author":"TE Scammell","year":"2017","unstructured":"Scammell TE, Arrigoni E, Lipton JO (2017) Neural circuitry of wakefulness and sleep. Neuron 93:747\u2013765","journal-title":"Neuron"},{"key":"6320_CR66","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/ijnp\/pyz007","volume":"22","author":"F Schifano","year":"2019","unstructured":"Schifano F, Chiappini S, Corkery JM, Guirguis A (2019) An insight into Z-drug abuse and dependence: an examination of reports to the European Medicines Agency database of suspected adverse drug reactions. Int J Neuropsychopharmacol 22:270\u2013277","journal-title":"Int J Neuropsychopharmacol"},{"key":"6320_CR67","doi-asserted-by":"crossref","unstructured":"Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA (2016) Assessment of the abuse potential of the orexin receptor antagonist, suvorexant, compared with zolpidem in a randomized crossover study. J Clin Psychopharmacol 36:314\u2013323","DOI":"10.1097\/JCP.0000000000000516"},{"key":"6320_CR68","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev.pa.09.040169.002411","volume":"9","author":"CR Schuster","year":"1969","unstructured":"Schuster CR, Thompson T (1969) Self administration of and behavioral dependence on drugs. Annu Rev Pharmacol 9:483\u2013502","journal-title":"Annu Rev Pharmacol"},{"key":"6320_CR69","doi-asserted-by":"publisher","first-page":"146164","DOI":"10.1016\/j.brainres.2019.02.026","volume":"1731","author":"SJ Simmons","year":"2020","unstructured":"Simmons SJ, Gentile TA (2020) Cocaine abuse and midbrain circuits: functional anatomy of hypocretin\/orexin transmission and therapeutic prospect. Brain Res 1731:146164","journal-title":"Brain Res"},{"key":"6320_CR70","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3389\/fnins.2020.00691","volume":"14","author":"S Soya","year":"2020","unstructured":"Soya S, Sakurai T (2020) Evolution of orexin neuropeptide system: structure and function. Front Neurosci 14:691","journal-title":"Front Neurosci"},{"key":"6320_CR71","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00213-013-3031-y","volume":"228","author":"WW Stoops","year":"2013","unstructured":"Stoops WW, Glaser PE, Rush CR (2013) Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users. Psychopharmacology 228:255\u2013262","journal-title":"Psychopharmacology"},{"key":"6320_CR72","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/13803395.2014.928268","volume":"36","author":"EK Stranks","year":"2014","unstructured":"Stranks EK, Crowe SF (2014) The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. J Clin Exp Neuropsychol 36:691\u2013700","journal-title":"J Clin Exp Neuropsychol"},{"key":"6320_CR73","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5664\/jcsm.5382","volume":"12","author":"H Sun","year":"2016","unstructured":"Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD (2016) Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea. J Clin Sleep Med 12:9\u201317","journal-title":"J Clin Sleep Med"},{"key":"6320_CR74","doi-asserted-by":"crossref","unstructured":"Thannickal TC, John J, Shan L, Swaab DF, Wu MF, Ramanathan L, McGregor R, Chew KT, Cornford M, Yamanaka A, Inutsuka A, Fronczek R, Lammers GJ, Worley PF, Siegel JM (2018) Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. Sci Transl Med 10","DOI":"10.1126\/scitranslmed.aao4953"},{"key":"6320_CR75","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/ageing\/afx167","volume":"47","author":"N Treves","year":"2018","unstructured":"Treves N, Perlman A, Kolenberg Geron L, Asaly A, Matok I (2018) Z-drugs and risk for falls and fractures in older adults \u2014 a systematic review and meta-analysis. Age Ageing 47:201\u2013208","journal-title":"Age Ageing"},{"key":"6320_CR76","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0165-0327(90)90009-W","volume":"19","author":"P Tyrer","year":"1990","unstructured":"Tyrer P, Murphy S, Riley P (1990) The benzodiazepine withdrawal symptom questionnaire. J Affect Disord 19:53\u201361","journal-title":"J Affect Disord"},{"key":"6320_CR77","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/jcph.523","volume":"55","author":"N Uemura","year":"2015","unstructured":"Uemura N, McCrea J, Sun H, Donikyan M, Zammit G, Liu R, Louridas B, Marsilio S, Lines C, Troyer MD, Wagner J (2015) Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects. J Clin Pharmacol 55:1093\u20131100","journal-title":"J Clin Pharmacol"},{"key":"6320_CR78","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1124\/dmd.120.000229","volume":"49","author":"T Ueno","year":"2021","unstructured":"Ueno T, Ishida T, Aluri J, Suzuki M, Beuckmann CT, Kameyama T, Asakura S, Kusano K (2021) Disposition and metabolism of [14C] lemborexant in healthy human subjects and characterization of its circulating metabolites. Drug Metab Dispos 49:31\u201338","journal-title":"Drug Metab Dispos"},{"key":"6320_CR79","doi-asserted-by":"crossref","unstructured":"Ufer M, Kelsh D, Schoedel KA, Dingemanse J (2022) Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep 14;45(3):zsab224","DOI":"10.1093\/sleep\/zsab224"},{"key":"6320_CR80","unstructured":"US Drug Enforcement Administration (2020) Schedules of controlled substances: placement of lemborexant in schedule IV. Fed Regist. https:\/\/www.federalregister.gov\/documents\/2020\/04\/07\/2020-07089\/schedules-of-controlled-substances-placement-of-lemborexant-in-schedule-iv. Accessed 2 Dec\u00a02020"},{"key":"6320_CR81","unstructured":"US Food and Drug Administration (2017) Assessment of abuse potential of drugs: guidance for industry. https:\/\/www.fda.gov\/media\/123819\/download. Accessed\u00a02 Dec 2020"},{"key":"6320_CR82","unstructured":"US Food and Drug Administration (2019) FDA adds boxed warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines. Drug Safety Communications. https:\/\/www.fda.gov\/media\/123819\/download. Accessed 2 Dec\u00a02020"},{"key":"6320_CR83","unstructured":"US Food and Drug Administration (2020) FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class. Drug Safety Communication.\u00a0https:\/\/www.fda.gov\/media\/142368\/download. Accessed 1 June\u00a02021"},{"key":"6320_CR84","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2165\/00023210-200418050-00003","volume":"18","author":"A Vermeeren","year":"2004","unstructured":"Vermeeren A (2004) Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 18:297\u2013328","journal-title":"CNS Drugs"},{"key":"6320_CR85","doi-asserted-by":"publisher","first-page":"zsy260","DOI":"10.1093\/sleep\/zsy260","volume":"42","author":"A Vermeeren","year":"2019","unstructured":"Vermeeren A, Jongen S, Murphy P, Moline M, Filippov G, Pinner K, Perdomo C, Landry I, Majid O, Van Oers ACM, Van Leeuwen CJ, Ramaekers JG, Vuurman E (2019) On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep 42:zsy260","journal-title":"Sleep"},{"key":"6320_CR86","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.5665\/sleep.5168","volume":"38","author":"A Vermeeren","year":"2015","unstructured":"Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van Oers AC, Palcza J, Li X, Laethem T, Heirman I, Bautmans A, Troyer MD, Wrishko R, McCrea J (2015) On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers. Sleep 38:1803\u20131813","journal-title":"Sleep"},{"key":"6320_CR87","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00213-016-4375-x","volume":"233","author":"A Vermeeren","year":"2016","unstructured":"Vermeeren A, Vets E, Vuurman EF, Van Oers AC, Jongen S, Laethem T, Heirman I, Bautmans A, Palcza J, Li X, Troyer MD, Wrishko R, McCrea J, Sun H (2016) On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly. Psychopharmacology 233:3341\u20133351","journal-title":"Psychopharmacology"},{"key":"6320_CR88","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.sleep.2021.01.048","volume":"80","author":"J Yardley","year":"2021","unstructured":"Yardley J, K\u00e4rpp\u00e4 M, Inoue Y, Pinner K, Perdomo C, Ishikawa K, Filippov G, Kubota N, Moline M (2021) Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Med 80:333\u2013342","journal-title":"Sleep Med"},{"key":"6320_CR89","doi-asserted-by":"publisher","first-page":"146028","DOI":"10.1016\/j.brainres.2018.11.023","volume":"1731","author":"S Zarrabian","year":"2020","unstructured":"Zarrabian S, Riahi E, Karimi S, Razavi Y, Haghparast A (2020) The potential role of the orexin reward system in future treatments for opioid drug abuse. Brain Res 1731:146028","journal-title":"Brain Res"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-023-06320-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-023-06320-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-023-06320-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T17:24:23Z","timestamp":1679851463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-023-06320-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["6320"],"URL":"https:\/\/doi.org\/10.1007\/s00213-023-06320-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742522698.793599108","asserted-by":"object"}]},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"assertion":[{"value":"27 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MM is an employee of Eisai Inc. IL is a former employee of Eisai Inc. SA is an employee of Eisai Co., Ltd. CB is a former Eisai Co., Ltd. BS is an employee of Altasciences. JA and JEH are employees of Pinney Associates, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}